About Automera
Automera is a company based in Singapore (Singapore) founded in 2022 by Michael Lazarou, Loong Wang, and Taiyang Zhang. Automera has raised $16 million across 1 funding round from investors including Accelerator, ClavystBio and Xora. Automera offers products and services including Degradation Platform. Automera operates in a competitive market with competitors including Sai Life Sciences, Acies Bio, Personal Chemistry, IRBM and NFIL, among others.
- Headquarter Singapore, Singapore
- Founders Michael Lazarou, Loong Wang, Taiyang Zhang
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Automera Pte. Ltd.
-
Annual Revenue
Not available
-
Net Profit
-$1.25 M (USD)0as on Dec 31, 2023
-
EBITDA
-$1.25 M (USD)0as on Dec 31, 2023
-
Total Equity Funding
$16 M (USD)
in 1 rounds
-
Latest Funding Round
$16 M (USD), Series A
Sep 05, 2023
-
Investors
Accelerator
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Automera
Automera offers a comprehensive portfolio of products and services, including Degradation Platform.
Platform designs molecules for autophagy-based disease targeting
Funding Insights of Automera
Automera has successfully raised a total of $16M through 1 strategic funding round. The most recent funding activity was a Series A round of $16 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Automera
Automera has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Accelerator, ClavystBio and Xora.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital services are offered for early-stage biotech companies.
|
Locked | Locked | Locked | |
|
Capital is provided by Xora to deep tech entrepreneurs.
|
Locked | Locked | Locked | |
|
Government-backed investments are directed toward healthcare, fintech, and various sectors.
|
Locked | Locked | Locked |
Investor details for Automera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Automera
Investment portfolio details for Automera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Automera
Detailed financials for Automera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Automera Comparisons
Peer comparison for Automera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Automera
Automera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sai Life Sciences, Acies Bio, Personal Chemistry, IRBM and NFIL, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Complex small molecules are discovered, developed, and manufactured for pharmaceuticals.
|
|
| Locked | Locked | Locked |
Provider of drug discovery and development services to pharmaceutical, biotech, and food industries
|
|
| Locked | Locked | Locked |
Coherent Synthesis is developed for medicinal and combinatorial chemistry applications.
|
|
| Locked | Locked | Locked |
Integrated drug discovery and preclinical development services are provided.
|
|
| Locked | Locked | Locked |
Fluorinated compounds are synthesized and manufactured customly for various industries.
|
|
| Locked | Locked | Locked |
Swiss fine chemicals company providing API, Intermediates and custom synthesis services for the pharma and biotech industry
|
Detailed competitors of Automera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Automera
Complete news archive for Automera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Automera
Automera was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Automera is headquartered in Singapore, Singapore.
Thong Le is the current CEO of Automera.
Automera is a funded company, having raised a total of $16M across 1 funding round to date.
Automera was founded in 2022 as a biotechnology research company. Autophagy-driven degradation of proteins is advanced using computational chemistry and artificial intelligence. A pipeline is maintained to target protein aggregates and related entities. Operations are conducted from bases in Seattle, Washington, and Singapore, with a focus on research and development in the sector.
Automera's top competitors include Sai Life Sciences, Acies Bio and Medicilon.
Automera offers Degradation Platform.
Automera has 4 investors. Key investors include Accelerator, ClavystBio, Xora, and EDBI.